[ main menu ]


Home Page

Diet, Fatty acids, and regulation of genes important for heart disease.

Conjugated linoleic acid inhibits proliferation and modulates protein kinase C isoforms in human prostate cancer cells.

Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus.

The effect of conjugated linoleic acid on calcium absorption and bone metabolism and composition in adult ovariectomised rats.

Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats.

Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease.

Safety profile of conjugated linoleic acid in a 12-month trial in obese humans.





Nutrition Report Update Internet Properties Include:

ALAUPDATE.COM

CLAUPDATE.COM

DRIBOSEUPDATE.COM

KRILLOILUPDATE.COM

LGLUTAMINEUPDATE.COM

PROSTATEUPDATE.COM

UTIUPDATE.COM




Title: Safety profile of conjugated linoleic acid in a 12-month trial in obese humans.

Author(s): Whigham LD, O'Shea M, Mohede IC, Walaski HP, Atkinson RL.

Source: Food Chem Toxicol. 2004 Oct;42(10):1701-9.

Content: Department of Medicine and Nutritional Sciences, University of Wisconsin, Madison 53706, USA.

Conjugated linoleic acid (CLA) is marketed in numerous commercially available dietary supplements, but few studies have looked at the long-term safety of this product.

The current study evaluated the safety of one CLA product (Clarinol) over a one-year period in obese humans who were generally healthy. This was a randomized, double-blind study consisting of three phases in which subjects were given 6 g/day of CLA or placebo.

Phase 1 was a low calorie diet (13 kcal/kg desirable weight) for 12 weeks or until 10-20% of initial body weight was lost.

In phase 2, from weeks 12 to 28, subjects were re-fed a diet providing 25-30 kcal/kg of desirable body weight.

Phase 3 was open label, with subjects from both groups taking CLA from weeks 28 to 52.

At biweekly visits, subjects completed a questionnaire evaluating side effects and adverse events. Blood was taken for assay of liver function, glucose, insulin, serum lipids, blood counts, and general chemistry.

Overall, body composition did not differ between groups. Laboratory tests showed no adverse effects of CLA. Adverse events and side effects were less in the CLA group compared to placebo. We conclude that CLA as Clarinol is safe for use in obese humans for at least one year. Copyright 2004 Elsevier Ltd.



More/Expanded Article Information: [ click here ]

Click Here To View A Conjugated Linoleic Acid (CLA) Supplier Website!

This site is a service of CCWEBGROUP that provides and reports interesting information that is available to the general public. CCWEBGROUP is not in any way involved in performing the scientific studies, completing the analyses, nor evaluating the results.

Many studies reported herein have been performed on laboratory animals and not on humans. While some results of animal trials are later found to be similar in human trials, we have no way of knowing whether or not this will be the case.

This information is not presented as medical advice and no conclusions regarding the effectiveness or lack of such should be drawn from this information.

As with any information that pertains to your health, please discuss your questions and/or conclusions with your physician or healthcare provider. You can order Tonalin CLA for fat loss!